TY  - GEN
AU  - Gould,Janet
AU  - Callis,Courtney M
AU  - Dolan,David G
AU  - Stanard,Brad
AU  - Weideman,Patricia A
TI  - Special endpoint and product specific considerations in pharmaceutical acceptable daily exposure derivation
SN  - 1096-0295
PY  - 2017///0309
KW  - Animals
KW  - Dose-Response Relationship, Drug
KW  - Drug Contamination
KW  - prevention & control
KW  - Drug Hypersensitivity
KW  - immunology
KW  - Drug Industry
KW  - legislation & jurisprudence
KW  - Drug-Related Side Effects and Adverse Reactions
KW  - Guidelines as Topic
KW  - Health Policy
KW  - Humans
KW  - Mutagenicity Tests
KW  - No-Observed-Adverse-Effect Level
KW  - Occupational Exposure
KW  - adverse effects
KW  - Occupational Health
KW  - Pharmaceutical Preparations
KW  - classification
KW  - Pharmacokinetics
KW  - Policy Making
KW  - Proteins
KW  - Risk Assessment
KW  - Toxicity Tests
KW  - methods
KW  - Toxicokinetics
N1  - Publication Type: Journal Article; Review
UR  - https://doi.org/10.1016/j.yrtph.2016.05.022
ER  -